Use of intrathecal bupivacaine in refractory chronic nonmalignant pain

Pain Medicine

Volumn 10, Issue 5, 2009, Pages 819-828

  Kumar, Krishna ^a,b   Bodani, Vivek ^a   Bishop, Sharon ^a   Tracey, Sherri ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b REGINA GENERAL HOSPITAL   (Canada)

Author keywords

Bupivacaine; Chronic pain; Efficacy; Intrathecal; Opioids; Safety

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BUPIVACAINE; CYCLOOXYGENASE 2 INHIBITOR; HYDROMORPHONE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; SPASMOLYTIC AGENT;

ADULT; AGED; ANOREXIA; APPLICATION SITE INFECTION; BECK DEPRESSION INVENTORY; CHRONIC PAIN; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DEPRESSION; DISABILITY; DISEASE CONTROL; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EUROQOL 5D; FEMALE; FUNCTIONAL STATUS; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; MENTAL HEALTH; NEUROLOGIC DISEASE; NIGHT SWEAT; OSWESTRY DISABILITY INDEX; PAIN ASSESSMENT; PARESTHESIA; PHYSICAL ACTIVITY; QUALITY OF LIFE; REVIEW; SEROMA; SHORT FORM 36; TREATMENT DURATION; VISUAL ANALOG SCALE; WEAKNESS; WORK RESUMPTION;

ADULT; AGED; ANALGESICS, OPIOID; ANESTHETICS, LOCAL; BUPIVACAINE; CHRONIC DISEASE; DEPRESSION; DISABILITY EVALUATION; DRUG IMPLANTS; DRUG RESISTANCE; FEMALE; HUMANS; INJECTIONS, SPINAL; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 68349125416     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2009.00640.x     Document Type: Review

References (44)

1. Deer T, Krames ES, Hassenbusch SJ, et al. Polyanalgesic Consensus Conference 2007: Recommendations for the management of pain by intrathecal (intraspinal) drug delivery: Report of an interdisciplinary expert panel. Neuromodulation 2007;10:300-28.
2. Merskey H, Bogduk N, eds. Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms, 2nd edition. Seattle, WA: IASP Press; 1994.
3. Krames ES. Intraspinal opioid therapy for chronic non-malignant pain: Current practice and clinical guidelines. J Pain Symptom Manage 1996;11:333-52.
4. Arner S, Arner B. Differential effects of epidural morphine in the treatment of cancer-related pain. Acta Anaesthesiol Scand 1985;29:32-6.
5. Arner S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1988;33:11-23.
6. Hammond DL. Do opioids relieve central pain? In: Casey KL, ed. Pain And Central Nervous System Disease: The Central Pain Syndromes. New York: Raven Press; 1991: 233-41.
7. Portenoy RK, Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: New hypotheses derived from studies of opioid infusions. Pain 1990;43:273-86.
8. Vecht CJ. Nociceptive nerve pain and neuropathic pain. Pain 1989;39:243-6.
9. Mironer YE, Haasis JC, Chapple I, Brown C, Satterthwaite JR. Efficacy and safety of intrathecal opioid/bupivacaine mixture in chronic nonmalignant pain: A double blind, randomized, crossover, multicenter study by the National Forum of Independent Pain Clinicians (NFIPC). Neuromodulation 2002;5:208-13.
10. Grudt TJ, Williams JT. Kappa-opioid receptors also increase potassium conductance. Proc Natl Acad Sci U S A 1993;90:11429-32.
11. Yoshimura M, North RA. Substantia gelatinosa neurones hyperpolarized in vitro by enkephalin. Nature 1983;305:529-30.
12. Besse D, Lombard MC, Zajac JM, Roques BP, Besson JM. Pre- and postsynaptic location of mu, delta, and kappa opioid receptors in the superficial layers of the dorsal horn of the rat spinal cord. Prog Clin Biol Res 1990;328:183-6.
13. Gouarderes C, Beaudet A, Zajac JM, Cros J, Quirion R. High resolution radioautographic localization of [125I]FK33-824-labelled mu opioid receptors in the spinal cord of normal and deafferented rats. Neuroscience 1991;43:197-209.
14. Yaksh TL. Pharmacology and mechanisms of opioid analgesic activity. In: Yaksh TL, Lynch C 3rd, Zapol WM, et al., eds. Anesthesia: Biologic Foundations. Philadelphia, PA: Lippincott-Raven; 1997: 921-34.
15. Aimone LD, Yaksh TL. Opioid modulation of capsaicin-evoked release of substance P from rat spinal cord in vivo. Peptides 1989;10:1127-31.
16. Go VL, Yaksh TL. Release of substance P from the cat spinal cord. J Physiol 1987;391:141-67.
17. Kaneko S, Fukuda K, Yada N, et al. Ca2+ channel inhibition by kappa opioid receptors expressed in Xenopus oocytes. Neuroreport 1994;5:2506-8.
18. Piros ET, Prather PL, Loh HH, et al. Ca2+ channel and adenylyl cyclase modulation by cloned mu-opioid receptors in GH3 cells. Mol Pharmacol 1995;47:1041-9.
19. Carter BD, Medzihradsky F. Go mediates the coupling of the mu opioid receptor to adenylyl cyclase in cloned neural cells and brain. Proc Natl Acad Sci U S A 1993;90:4062-6.
20. Krames ES, Lanning RM. Intrathecal infusional analgesia for nonmalignant pain: Analgesic efficacy of intrathecal opioid with or without bupivacaine. J Pain Symptom Manage 1993;8:539-48.
21. Akerman B, Arwestrom E, Post C. Local anesthetics potentiate spinal morphine antinociception. Anesth Analg 1988;67:943-8.
22. Chaplan SR, Bach FW, Shafer SL, Yaksh TL. Prolonged alleviation of tactile allodynia by intravenous lidocaine in neuropathic rats. Anesthesiology 1995;83:775-85.
23. Penning JP, Yaksh TL. Interaction of intrathecal morphine with bupivacaine and lidocaine in the rat. Anesthesiology 1992;77:1186-200.
24. Sjoberg M, Appelgren L, Einarsson S, et al. Long-term intrathecal morphine and bupivacaine in "refractory"cancer pain. I. Results from the first series of 52 patients. Acta Anaesthesiol Scand 1991;35:30-43.
25. Tejwani GA, Rattan AK, McDonald JS. Role of spinal opioid receptors in the antinociceptive interactions between intrathecal morphine and bupivacaine. Anesth Analg 1992;74:726-34.
26. Bennett G, Burchiel K, Buchser E, et al. Clinical guidelines for intraspinal infusion: Report of an expert panel. J Pain Symptom Manage 2000;20:S37-43.
27. Dahm P, Nitescu P, Appelgren L, Curelaru I. Continuous intrathecal infusion of opioid and bupivacaine in the treatment of refractory pain due to postherpetic neuralgia: A case report. Neuromodulation 1998;1:85-9.
28. Dahm PO, Nitescu PV, Appelgren LK, Curelaru ID. Long-term intrathecal infusion of opioid and/or bupivacaine in the prophylaxis and treatment of phantom limb pain. Neuromodulation 1998;1:111-28.
29. Dario A, Marra A, Marra P, Dorizzi A. Intrathecal administration of different drugs by programmable infusion device in chronic pain: A case report. Neuromodulation 1998;1:107-10.
30. Deer TR, Caraway DL, Kim CK, et al. Clinical experience with intrathecal bupivacaine in combination with opioid for the treatment of chronic pain related to failed back surgery syndrome and metastatic cancer pain of the spine. Spine J 2002;2:274-8.
31. Lundborg C, Dahm P, Nitescu P, Appelgren L, Curelaru I. Clinical experience using intrathecal (IT) bupivacaine infusion in three patients with complex regional pain syndrome type I (CRPS-I). Acta Anaesthesiol Scand 1999;43:667-78.
32. Lundborg CN, Nitescu PV, Appelgren LK, Curelaru ID. Long-term intrathecal (IT) administration of opioid and bupivacaine relieved intractable pain in a patient with familial amyloidosis polyneuropathy: A case report. Neuromodulation 1998;1:199-208.
33. Nitescu P, Dahm P, Appelgren L, Curelaru I. Continuous infusion of opioid and bupivacaine by externalized intrathecal catheters in long-term treatment of "refractory"nonmalignant pain. Clin J Pain 1998;14:17-28.
34. Fairbank JC, Pynsent PB. The Oswestry Disability Index. Spine 2000;25:2940-52.
35. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71.
36. EuroQol Group. EuroQol - A new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
37. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey: II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247-63.
38. Wallace M, Yaksh TL. Long-term spinal analgesic delivery: A review of the preclinical and clinical literature. Reg Anesth Pain Med 2000;25:117-57.
39. Dolan P, Gudex C, Kind P, Williams A. A Social Tariff for EuroQol: Results from a UK General Population Survey. University of York Centre for Health Economics Discussion Paper Series (no. 138). York: Center for Health Economics; 1995.
40. Classen AM, Wimbish GH, Kupiec TC. Stability of admixture containing morphine sulfate, bupivacaine hydrochloride, and clonidine hydrochloride in an implantable infusion system. J Pain Symptom Manage 2004;28:603-11.
41. Hildebrand KR, Elsberry DD, Deer TR. Stability, compatibility, and safety of intrathecal bupivacaine administered chronically via an implantable delivery system. Clin J Pain 2001;17:239-44.
42. Meyer-Rosberg K, Burckhardt CS, Huizar K, et al. A comparison of the SF-36 and Nottingham Health Profile in patients with chronic neuropathic pain. Eur J Pain 2001;5:391-403.
43. Anderson VC, Burchiel KJ. A prospective study of long-term intrathecal morphine in the management of chronic nonmalignant pain. Neurosurgery 1999;44:289-300.
44. Paice JA, Penn RD, Shott S. Intraspinal morphine for chronic pain: A retrospective, multicenter study. J Pain Symptom Manage 1996;11:71-80.